RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
31.50
-0.17 (-0.54%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close31.67
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume1,104,140
Market Cap215.642B
Beta (3Y Monthly)0.35
PE Ratio (TTM)20.52
EPS (TTM)1.54
Earnings DateN/A
Forward Dividend & Yield1.08 (3.44%)
Ex-Dividend Date2018-03-15
1y Target Est33.70
Trade prices are not sourced from all markets
  • Reuters3 hours ago

    Gilead Sciences snares Roche executive O'Day as CEO

    Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1, 2019 until O'Day's start date of March 1, 2019. O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland.

  • Gilead Sciences snares Roche executive O'Day as CEO
    Reuters3 hours ago

    Gilead Sciences snares Roche executive O'Day as CEO

    Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1, 2019 until O'Day's start date of March 1, 2019. O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland.

  • Financial Times1 hour ago

    [$$] US drugmaker Gilead appoints Roche executive as new chief

    from Gilead was announced in July. At the same time, Gilead said chairman John Martin would also leave. Mr Milligan became CEO of Gilead in 2016 and had spent almost three decades with the business before announcing his plans to step aside.

  • The Wall Street Journal3 hours ago

    Struggling Gilead Taps Roche Executive as New CEO

    to take the helm and help the drug company revive sales and recover from a disappointing deal. In the role, Mr. O’Day oversaw successful launches of several new cancer and other drugs and turned the business into a top industry performer. The Foster City, Calif., company is at a pivotal juncture as it looks to jump-start revenue growth and its stock price amid declining sales of its lucrative hepatitis C drugs, including Sovaldi and Harvoni.

  • GlobeNewswire4 hours ago

    New member proposed for election to Roche Board of Directors

    Basel, 10 December 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the ...

  • GlobeNewswire4 hours ago

    Changes to the Roche Corporate Executive Committee

    OTCQX: RHHBY) today announced that Daniel O`Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. Until the end of February 2019 and prior to assuming new responsibilities outside of Roche, he will provide his support to ensure a smooth transition of activities. William (Bill) Anderson, currently CEO of Genentech, will be appointed CEO Roche Pharmaceuticals effective 1 January 2019.

  • Benzinga3 days ago

    The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 6) Gritstone Oncology Inc (NASDAQ: GRTS ) Down In The Dumps ...

  • Reuters3 days ago

    Roche's lung cancer combo treatment wins FDA approval

    The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer. The drug, however, has trailed Merck's (MRK.N) Keytruda and Bristol Myers Squibb's (BMY.N) Opdivo in revenue as those medicines beat it to market in other indications.

  • Reuters3 days ago

    Roche's lung cancer combo treatment wins FDA approval

    Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer. The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC) live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer.

  • GlobeNewswire3 days ago

    FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

    OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.

  • Reuters3 days ago

    Roche's lung cancer combo treatment wins FDA approval

    Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a type of lung cancer. The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer live significantly longer, compared with Avastin and chemotherapy, the company said in a statement. The drug on Wednesday had also won priority review from the U.S. regulator for treating patients with untreated extensive-stage small cell lung cancer.

  • Roche's Kadcyla Halves Death Risk in Breast Cancer Study
    Zacks4 days ago

    Roche's Kadcyla Halves Death Risk in Breast Cancer Study

    Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

  • Business Wire3 days ago

    FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

  • AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study
    Zacks4 days ago

    AbbVie Halts Rova-T Phase III Second-Line Lung Cancer Study

    IDMC recommends AbbVie (ABBV) to stop enrolment in a late-stage study on its small cell lung cancer candidate, Rova-T.

  • Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx
    Zacks4 days ago

    Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

    Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer.

  • J&J's Blood Cancer Drugs Succeed in Label Expansion Studies
    Zacks5 days ago

    J&J's Blood Cancer Drugs Succeed in Label Expansion Studies

    J&J (JNJ) presents positive data from late-stage studies evaluating its blood cancer drugs, Imbruvica and Darzalex, in the first-line setting at ASH.

  • Roche's Tecentriq Combination Gets Priority Review by FDA
    Zacks5 days ago

    Roche's Tecentriq Combination Gets Priority Review by FDA

    The FDA accepts and grants Priority Review to Roche's (RHHBY) sBLA for Tecentriq in combination with carboplatin and etoposide for the initial treatment of patients withextensive-stage small cell lung cancer.

  • GlobeNewswire5 days ago

    Roche's Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment

    At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Herceptin, an 11.3% ...

  • Reuters5 days ago

    Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

    ZURICH (Reuters) - Roche's (ROG.S) Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company ...

  • Reuters5 days ago

    Roche's Tecentriq wins speedy U.S. review in small cell lung cancer

    Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer , the company said, setting up possible approval ...

  • GlobeNewswire5 days ago

    FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

    OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company`s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). The FDA is expected to make a decision on approval by 18 March 2019. A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease.

  • Business Wire5 days ago

    FDA Grants Priority Review to Genentech’s Tecentriq in Combination with Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES-SCLC). The FDA is expected to make a decision on approval by March 18, 2019. A Priority Review designation is granted to medicines that the FDA has determined to have the potential to provide significant improvements in the treatment, prevention or diagnosis of a serious disease.

  • Roche Announces Positive Data on Venclexta/Venclyxto at ASH
    Zacks6 days ago

    Roche Announces Positive Data on Venclexta/Venclyxto at ASH

    Roche (RHHBY) announces new Venclexta/Venclyxto data that demonstrate deep responses in two of the most common types of leukaemia.

  • GuruFocus.com6 days ago

    Eye Drug Continues to Drive Regeneron's Growth

    The key driver behind the growth of biotech giant Regeneron Pharmaceuticals Inc. (REGN) may be facing competition, but not imminently. Right now, Regeneron's Eylea shares the top spot with Lucentis in the worldwide market for drugs to treat wet age-related macular degeneration (AMD). Lucentis is marketed by Novartis (NVS) outside North America and Roche (RHHBY) elsewhere in the world.